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Randomization Analyses in
Selection of Secretory
Phospholipase A2-IIA as a
Valid Therapeutic Target for
Prevention of Cardiovascular DiseaseWe appreciate the remarks of Drs. Rosenson and Hurt-Camejo
regarding our work (1). We agree that the association of levels of
secretory phospholipase A2-IIA (sPLA2-IIA) mass and sPLA2
enzyme activity may differ in subjects with and without coronary
heart disease (CHD). For this reason, all analyses were conducted
separately for the general population and for those with acute
coronary syndrome.
As expressed in multiple places throughout the report, sPLA2
activity was not used as a proxy of sPLA2-IIA activity but as a
composite of several sPLA2 isoenzymes.
The single nucleotide polymorphism showing the strongest as-
sociation with PLA2G2A messenger RNA expression (rs10732279)
was in very strong linkage disequilibrium (R2 ¼ 0.91) with the
PLA2G2A rs11573156 variant used for our Mendelian randomi-
zation analysis.
The correlation between sPLA2-IIA mass and sPLA2 enzyme
activity was moderate at best and does not imply a similar
magnitude of association of the PLA2G2A rs11573156 variant
with both of these measures. Because the mass assay is speciﬁc for
sPLA2-IIA, but the activity assay is not, it is not surprising that
rs11573156 showed a stronger association with mass than with
activity.
sPLA2-IIA mass and sPLA2 enzyme activity were non-
normally distributed, and therefore, these variables were log
transformed for analysis. The difference in log values equates to theproportional difference in sPLA2-IIA mass and activity between
the 2 groups.
The correspondents failed to read Online Table 11 carefully, in
which values are differences in sPLA2-IIA mass on the absolute
scale from treatment with 500 mg/day varespladib versus placebo
pooled across the randomized controlled trials. The value (13.13
pmol/l) for sPLA2-IIA mass corresponds to a 78% reduction in
sPLA2-IIA mass (reported in the Results section), which is com-
parable to the 80% value to which the correspondents refer.
We did not specify a cut point of 500 participants for the
inclusion of trial data; however, we reported information on the
pooled effects of varespladib on biomarkers available in more
than 500 subjects in total across all trials of varespladib.
We did not ﬁnd evidence of a differential effect of varespladib
on sPLA2-IIA mass or low-density lipoprotein cholesterol level
when stratiﬁed by trials of patients with acute coronary syndrome
or stable CHD (p ¼ 0.48 and p ¼ 0.42 for heterogeneity,
respectively).
The review cited by the correspondents refers to 2 identical
studies that we discussed (Online Fig. 1) and cited, providing ev-
idence that the median inhibitory concentration values for vares-
pladib are lower for IIA (9 to 14 nmol/l) than for V or X (77 and 15
nmol/l, respectively).
We agree that varespladib is a nonspeciﬁc sPLA2 inhibitor,
and the genetic variant we studied was speciﬁc for sPLA2-IIA
mass. This is why we stated repeatedly that our analysis informs
on sPLA2-IIA as a therapeutic target, but not other sPLA2
isoforms.
We stand by the validity of our study and maintain our
conclusion that sPLA2-IIA is unlikely to play a causal role in
CHD.*Michael V. Holmes, MBBS, MSc
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